| Assay ID | Title | Year | Journal | Article |
|---|
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1346057 | Human lysine demethylase 6B (1.14.11.- Histone demethylases) | 2014 | ChemMedChem, Mar, Volume: 9, Issue:3
| A cell-permeable ester derivative of the JmjC histone demethylase inhibitor IOX1. |
| AID1346023 | Human lysine demethylase 4C (1.14.11.- Histone demethylases) | 2014 | ChemMedChem, Mar, Volume: 9, Issue:3
| A cell-permeable ester derivative of the JmjC histone demethylase inhibitor IOX1. |
| AID1346163 | Human egl-9 family hypoxia inducible factor 1 (1.14.11.29 2-oxoglutarate oxygenases) | 2014 | ChemMedChem, Mar, Volume: 9, Issue:3
| A cell-permeable ester derivative of the JmjC histone demethylase inhibitor IOX1. |
| AID1346053 | Human lysine demethylase 3A (1.14.11.- Histone demethylases) | 2014 | ChemMedChem, Mar, Volume: 9, Issue:3
| A cell-permeable ester derivative of the JmjC histone demethylase inhibitor IOX1. |
| AID1066184 | Inhibition of recombinant JMJD2C (unknown origin) incubated for 15 mins prior to substrate addition by AlphaScreen method | 2014 | Journal of medicinal chemistry, Jan-09, Volume: 57, Issue:1
| Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities. |
| AID1066176 | Induction of histone methylation in human HeLa cells assessed as H3K9me3 level after 72 hrs by immunofluorescence assay | 2014 | Journal of medicinal chemistry, Jan-09, Volume: 57, Issue:1
| Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities. |
| AID1885288 | Inhibition of N-terminal His-tagged human KDM4A using ARK(me3)STGGK peptide as substrate preincubated for 15 mins followed by susbtrate addition measured by matrix-assisted laser desorption/ionization-time-of-flight (MALDI-TOF) mass spectrometry method | 2022 | Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
| Recent Advances with KDM4 Inhibitors and Potential Applications. |
| AID1249066 | Inhibition of KDM2A (unknown origin) | 2014 | MedChemComm, Dec-01, Volume: 5, Issue:12
| Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor. |
| AID1256758 | Intrinsic aqueous solubility of the compound after 24 hrs by UV spectrophotometric analysis | 2015 | European journal of medicinal chemistry, Nov-13, Volume: 105 | Novel 5-carboxy-8-HQ based histone demethylase JMJD2A inhibitors: introduction of an additional carboxyl group at the C-2 position of quinoline. |
| AID1066183 | Inhibition of recombinant JMJD2E (unknown origin) incubated for 15 mins prior to substrate addition by AlphaScreen method | 2014 | Journal of medicinal chemistry, Jan-09, Volume: 57, Issue:1
| Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities. |
| AID1289360 | Inhibition of human Flag-tagged KDM4A expressed in human HeLa cells assessed as increase in H3K9me3 level after 24 hrs by DAPI staining based immunofluorescence assay | 2016 | Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
| Recent Progress in Histone Demethylase Inhibitors. |
| AID1289358 | Inhibition of human N-terminal His6-tagged KDM4E catalytic domain (1 to 337 residues) expressed in Escherichia coli using ARK(me3)STGGK as substrate preincubated for 15 mins measured after 30 mins by FDH coupled enzyme assay | 2016 | Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
| Recent Progress in Histone Demethylase Inhibitors. |
| AID1066186 | Inhibition of recombinant FBXL11 (unknown origin) incubated for 15 mins prior to substrate addition by AlphaScreen method | 2014 | Journal of medicinal chemistry, Jan-09, Volume: 57, Issue:1
| Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities. |
| AID1066181 | Inhibition of recombinant JMJD3 (unknown origin) incubated for 15 mins prior to substrate addition by AlphaScreen method | 2014 | Journal of medicinal chemistry, Jan-09, Volume: 57, Issue:1
| Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities. |
| AID1256752 | Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay | 2015 | European journal of medicinal chemistry, Nov-13, Volume: 105 | Novel 5-carboxy-8-HQ based histone demethylase JMJD2A inhibitors: introduction of an additional carboxyl group at the C-2 position of quinoline. |
| AID1256755 | Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay | 2015 | European journal of medicinal chemistry, Nov-13, Volume: 105 | Novel 5-carboxy-8-HQ based histone demethylase JMJD2A inhibitors: introduction of an additional carboxyl group at the C-2 position of quinoline. |
| AID1256754 | Inhibition of recombinant human JMJD2A using biotinylated histone H3 as substrate by AlphaScreen assay | 2015 | European journal of medicinal chemistry, Nov-13, Volume: 105 | Novel 5-carboxy-8-HQ based histone demethylase JMJD2A inhibitors: introduction of an additional carboxyl group at the C-2 position of quinoline. |
| AID1916573 | Inhibition of KDM4B (unknown origin) expressed in Escherichia coli and measured after 1 hrs by alpha screen assay | 2021 | Journal of medicinal chemistry, 11-25, Volume: 64, Issue:22
| Structure-Based Design of Selective Fat Mass and Obesity Associated Protein (FTO) Inhibitors. |
| AID1066182 | Inhibition of recombinant JARID1C (unknown origin) incubated for 15 mins prior to substrate addition by AlphaScreen method | 2014 | Journal of medicinal chemistry, Jan-09, Volume: 57, Issue:1
| Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities. |
| AID1916570 | Inhibition of KDM4E (unknown origin) expressed in Escherichia coli and measured after 1 hrs by alpha screen assay | 2021 | Journal of medicinal chemistry, 11-25, Volume: 64, Issue:22
| Structure-Based Design of Selective Fat Mass and Obesity Associated Protein (FTO) Inhibitors. |
| AID1824260 | Inhibition of recombinant NDM-1 (unknown origin) using fluorocillin as substrate at 30 uM incubated for 30 mins by fluorescence based assay | 2022 | European journal of medicinal chemistry, Jan-15, Volume: 228 | Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases. |
| AID1530562 | Antiplasmodial activity against asynchronous form of Plasmodium falciparum 3D7 infected in human erythrocytes assessed as parasite growth inhibition at 10 uM after 48 hrs by SYBR green1 staining based flow cytometry relative to control | 2019 | European journal of medicinal chemistry, Jan-01, Volume: 161 | Identification of novel quinazoline derivatives as potent antiplasmodial agents. |
| AID1916569 | Inhibition of KDM5C (unknown origin) expressed in Escherichia coli and measured after 1 hrs by alpha screen assay | 2021 | Journal of medicinal chemistry, 11-25, Volume: 64, Issue:22
| Structure-Based Design of Selective Fat Mass and Obesity Associated Protein (FTO) Inhibitors. |
| AID1249068 | Inhibition of KDM5C (unknown origin) | 2014 | MedChemComm, Dec-01, Volume: 5, Issue:12
| Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor. |
| AID1543453 | Inhibition of recombinant human PHD2 using 2OG as substrate and Fe2 as co-factor assessed as hydroxylation incubated for 15 mins in presence of L-ascorbate by LC-MS analysis | 2019 | Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
| Inhibition of a viral prolyl hydroxylase. |
| AID721522 | Inhibition of human FIH catalytic domain Mn2 expressed in Escherichia coli by NMR spectroscopic analysis | 2013 | Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
| Reporter ligand NMR screening method for 2-oxoglutarate oxygenase inhibitors. |
| AID1249065 | Inhibition of KDM3A (unknown origin) | 2014 | MedChemComm, Dec-01, Volume: 5, Issue:12
| Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor. |
| AID734755 | Inhibition of human hexahistidine-tagged full-length FTO expressed in Escherichia coli BL21 (DE3) using 3-methylthymidine as substrate assessed as inhibition of 3-methylthymidine conversion to thymidine after 1 hr by liquid chromatographic analysis | 2013 | Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
| Structural basis for inhibition of the fat mass and obesity associated protein (FTO). |
| AID700451 | Inhibition of JMJD2A catalytic domain by mass spectrophotometric analysis | 2012 | European journal of medicinal chemistry, Oct, Volume: 56 | Oncoepigenomics: making histone lysine methylation count. |
| AID1916572 | Inhibition of KDM4C (unknown origin) expressed in Escherichia coli and measured after 1 hrs by alpha screen assay | 2021 | Journal of medicinal chemistry, 11-25, Volume: 64, Issue:22
| Structure-Based Design of Selective Fat Mass and Obesity Associated Protein (FTO) Inhibitors. |
| AID1916575 | Inhibition of KDM3A (unknown origin) expressed in Escherichia coli and measured after 1 hrs by alpha screen assay | 2021 | Journal of medicinal chemistry, 11-25, Volume: 64, Issue:22
| Structure-Based Design of Selective Fat Mass and Obesity Associated Protein (FTO) Inhibitors. |
| AID1249054 | Inhibition of KDM4E (unknown origin) | 2014 | MedChemComm, Dec-01, Volume: 5, Issue:12
| Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor. |
| AID1256751 | Cytotoxicity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay | 2015 | European journal of medicinal chemistry, Nov-13, Volume: 105 | Novel 5-carboxy-8-HQ based histone demethylase JMJD2A inhibitors: introduction of an additional carboxyl group at the C-2 position of quinoline. |
| AID1810106 | Inhibition of recombinant human MINA53 expressed in Escherichia coli BL21 (DE3) using RPL27A G31RGNAGGLHHHRINFDKYHP49 as substrate preincubated for 15 mins followed by substrate addition and measured after 30 to 60 mins by RapidFire Mass spectrometry assa | 2021 | Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
| First-in-Class Inhibitors of the Ribosomal Oxygenase MINA53. |
| AID721523 | Inhibition of human PHD2 catalytic domain (181 to 426) Mn2 expressed in Escherichia coli by NMR spectroscopic analysis | 2013 | Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
| Reporter ligand NMR screening method for 2-oxoglutarate oxygenase inhibitors. |
| AID1249069 | Inhibition of KDM6B (unknown origin) | 2014 | MedChemComm, Dec-01, Volume: 5, Issue:12
| Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor. |
| AID721524 | Binding affinity to human FIH catalytic domain Mn2 expressed in Escherichia coli by NMR spectroscopic analysis | 2013 | Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
| Reporter ligand NMR screening method for 2-oxoglutarate oxygenase inhibitors. |
| AID1289359 | Inhibition of human N-terminal His6-tagged KDM4E catalytic domain (1 to 337 residues) expressed in Escherichia coli using ARK(me3)STGGK as substrate preincubated for 15 mins measured after 30 mins by MALDI-TOF mass spectrometric analysis | 2016 | Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
| Recent Progress in Histone Demethylase Inhibitors. |
| AID721525 | Binding affinity to human PHD2 catalytic domain (181 to 426) Mn2 expressed in Escherichia coli by NMR spectroscopic analysis | 2013 | Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
| Reporter ligand NMR screening method for 2-oxoglutarate oxygenase inhibitors. |
| AID1755691 | Inhibition of Salmonella typhimurium LsrK expressed in Escherichia coli MET1158 in presence of DPD by kinase-glo max luminescent assay | 2020 | Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
| Tackling Antimicrobial Resistance with Small Molecules Targeting LsrK: Challenges and Opportunities. |
| AID1916576 | Inhibition of KDM4A (unknown origin) expressed in Escherichia coli and measured after 1 hrs by alpha screen assay | 2021 | Journal of medicinal chemistry, 11-25, Volume: 64, Issue:22
| Structure-Based Design of Selective Fat Mass and Obesity Associated Protein (FTO) Inhibitors. |
| AID1916578 | Inhibition of KDM6B (unknown origin) expressed in Escherichia coli and measured after 1 hrs by alpha screen assay | 2021 | Journal of medicinal chemistry, 11-25, Volume: 64, Issue:22
| Structure-Based Design of Selective Fat Mass and Obesity Associated Protein (FTO) Inhibitors. |
| AID1256759 | Partition co-efficient, log D of the compound at pH 7.4 | 2015 | European journal of medicinal chemistry, Nov-13, Volume: 105 | Novel 5-carboxy-8-HQ based histone demethylase JMJD2A inhibitors: introduction of an additional carboxyl group at the C-2 position of quinoline. |
| AID1810105 | Inhibition of recombinant human NO66 expressed in Escherichia coli BL21 (DE3) using RPL8 N205PVEHPFGGGNHQHIGKPST224 as substrate preincubated for 15 mins followed by substrate addition and measured after 30 to 60 mins by RapidFire Mass spectrometry assay | 2021 | Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
| First-in-Class Inhibitors of the Ribosomal Oxygenase MINA53. |
| AID1066178 | Induction of histone methylation in human HeLa cells assessed as H3K4me3 level after 72 hrs by immunofluorescence assay | 2014 | Journal of medicinal chemistry, Jan-09, Volume: 57, Issue:1
| Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities. |
| AID1853071 | Inhibition of N-terminal His6-tagged TET2 (unknown origin) expressed in Escherichia coli assessed as reduction in hmC and fC levels preincubated for 30 mins followed by Fe(II) addition and measured after 1 hrs using 5'-CACmCGGTG-3' palindromic oligonucleo | 2022 | RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12
| A high-throughput effector screen identifies a novel small molecule scaffold for inhibition of ten-eleven translocation dioxygenase 2. |
| AID1066185 | Inhibition of recombinant JMJD1A (unknown origin) incubated for 15 mins prior to substrate addition by AlphaScreen method | 2014 | Journal of medicinal chemistry, Jan-09, Volume: 57, Issue:1
| Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities. |
| AID1256760 | Permeability of the compound at 10 mM after 4 hrs by PAMPA | 2015 | European journal of medicinal chemistry, Nov-13, Volume: 105 | Novel 5-carboxy-8-HQ based histone demethylase JMJD2A inhibitors: introduction of an additional carboxyl group at the C-2 position of quinoline. |
| AID1543452 | Inhibition of N-terminal His6-tagged recombinant Paramecium bursaria chlorella virus 1 CPH expressed in Escherichia coli Rosetta 2 (DE3) cells pre-incubated for 5 mins before 2OG as substrate and Fe2 as co-factor addition in presence of L-ascorbate and me | 2019 | Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
| Inhibition of a viral prolyl hydroxylase. |
| AID1256753 | Displacement of F-HIF1alpha from PHD2 (unknown origin) at 50 uM by fluorescence polarization assay relative to control | 2015 | European journal of medicinal chemistry, Nov-13, Volume: 105 | Novel 5-carboxy-8-HQ based histone demethylase JMJD2A inhibitors: introduction of an additional carboxyl group at the C-2 position of quinoline. |
| AID1916577 | Inhibition of KDM6A (unknown origin) expressed in Escherichia coli using Biotin-H3(14-34)K27me3 peptide and measured after 1 hrs by alpha screen assay | 2021 | Journal of medicinal chemistry, 11-25, Volume: 64, Issue:22
| Structure-Based Design of Selective Fat Mass and Obesity Associated Protein (FTO) Inhibitors. |
| AID1066175 | Induction of histone methylation in human HeLa cells assessed as H3K9me2 level after 72 hrs by immunofluorescence assay | 2014 | Journal of medicinal chemistry, Jan-09, Volume: 57, Issue:1
| Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities. |
| AID1824262 | Inhibition of recombinant NDM-1 (unknown origin) using fluorocillin as substrate at 3 uM incubated for 30 mins by fluorescence based assay | 2022 | European journal of medicinal chemistry, Jan-15, Volume: 228 | Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases. |
| AID1066177 | Induction of histone methylation in human HeLa cells assessed as H3K4me2 level after 72 hrs by immunofluorescence assay | 2014 | Journal of medicinal chemistry, Jan-09, Volume: 57, Issue:1
| Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities. |
| AID1916574 | Inhibition of KDM2A (unknown origin) expressed in Escherichia coli and measured after 1 hrs by alpha screen assay | 2021 | Journal of medicinal chemistry, 11-25, Volume: 64, Issue:22
| Structure-Based Design of Selective Fat Mass and Obesity Associated Protein (FTO) Inhibitors. |
| AID721519 | Displacement of 2OG from FBXL11 (1 to 517) (unknown origin) expressed in Escherichia coli at 800 uM | 2013 | Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
| Reporter ligand NMR screening method for 2-oxoglutarate oxygenase inhibitors. |
| AID1530563 | Antiplasmodial activity against asynchronous form of Plasmodium falciparum 3D7 infected in human erythrocytes assessed as parasite growth inhibition after 48 hrs by SYBR green1 staining based flow cytometry | 2019 | European journal of medicinal chemistry, Jan-01, Volume: 161 | Identification of novel quinazoline derivatives as potent antiplasmodial agents. |
| AID1916571 | Inhibition of KDM4D (unknown origin) expressed in Escherichia coli and measured after 1 hrs by alpha screen assay | 2021 | Journal of medicinal chemistry, 11-25, Volume: 64, Issue:22
| Structure-Based Design of Selective Fat Mass and Obesity Associated Protein (FTO) Inhibitors. |
| AID1249064 | Inhibition of KDM4C (unknown origin) | 2014 | MedChemComm, Dec-01, Volume: 5, Issue:12
| Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor. |
| AID700433 | Inhibition of JMJD2E catalytic domain by mass spectrophotometric analysis | 2012 | European journal of medicinal chemistry, Oct, Volume: 56 | Oncoepigenomics: making histone lysine methylation count. |
| AID1824261 | Inhibition of recombinant NDM-1 (unknown origin) using fluorocillin as substrate at 10 uM incubated for 30 mins by fluorescence based assay | 2022 | European journal of medicinal chemistry, Jan-15, Volume: 228 | Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases. |
| AID721528 | Displacement of 2OG from FIH (unknown origin) expressed in Escherichia coli at 400 uM | 2013 | Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
| Reporter ligand NMR screening method for 2-oxoglutarate oxygenase inhibitors. |
| AID721529 | Displacement of 2OG from catalytic domain of PHD2 (181 to 426) (unknown origin) expressed in Escherichia coli at 400 uM | 2013 | Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
| Reporter ligand NMR screening method for 2-oxoglutarate oxygenase inhibitors. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID977608 | Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB | 2013 | Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
| Structural basis for inhibition of the fat mass and obesity associated protein (FTO). |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |